Asset profile
Rademikibart
Monoclonal antibody
Evidence outlook · results not reported
NCT05017480 · Atopic Dermatitis
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
NCT05017480: The study was randomized, quadruple-blind, placebo-controlled, and included 330 participants, with a clinical primary endpoint based on validated Investigator Global Assessment. Although the reported primary response favored rademikibart (29.0% vs 5.9%), the registry does not state whether the primary comparison was statistically significant, so the result remains unclear.
Also in development:Chronic Obstructive Pulmonary Disease · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
107 competitors in this universe: 6 direct rivals (same mechanism and indication), 0 same-class, 101 same-indication; 27 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Rademikibart: this drug | Phase 3 | Monoclonal antibody | IL-4R-alpha | ||
| Dupilumab (Dupixent) | Approved | Monoclonal antibody | IL-4R-alpha | ||
| GS101 | Phase 3 | Monoclonal antibody | IL-4R-alpha | ||
| Manfidokimab | Phase 3 | Monoclonal antibody | IL-4R-alpha | ||
| QL2108 | Phase 3 | Monoclonal antibody | IL-4R-alpha | ||
| Stapokibart | Phase 3 | Monoclonal antibody | IL-4R-alpha | ||
| CKD-706 | Phase 1 | Monoclonal antibody | IL-4R-alpha | ||
| Abrocitinib (Cibinqo) | Approved | Small molecule | JAK1 | ||
| Aclidinium Bromide (Tudorza Pressair) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3) | ||
| Aclidinium Bromide / Formoterol Fumarate (Duaklir Pressair) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | ||
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | ||
| Benralizumab (Fasenra) | Approved | Monoclonal antibody | IL-5 receptor alpha, IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC), IL-5 receptor alpha (IL5RA) on eosinophils/basophils | ||
| Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere) | Approved | Small molecule | Glucocorticoid receptor; Muscarinic M3; Beta-2 adrenergic | ||
| Crisaborole (Eucrisa) | Approved | Small molecule | PDE4 | ||
| Depemokimab | Approved | Monoclonal antibody | IL-5 | ||
| Difamilast (Moizerto / Adquey) | Approved | Small molecule | PDE4 |
…and 92 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.